421 related articles for article (PubMed ID: 18837727)
1. Etanercept provides a more physiological approach in the treatment of psoriasis.
Altomare G; Ayala F; Berardesca E; Chimenti S; Giannetti A; Girolomoni G; Lotti T; Martini P; Peserico A; Guerra AP; Vena GA
Dermatol Ther; 2008 Oct; 21 Suppl 2():S1-14. PubMed ID: 18837727
[TBL] [Abstract][Full Text] [Related]
2. Etanercept for psoriasis: two case reports.
Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
4. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
Mease PJ
Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
[TBL] [Abstract][Full Text] [Related]
5. Treatment of erythrodermic psoriasis with etanercept.
Esposito M; Mazzotta A; de Felice C; Papoutsaki M; Chimenti S
Br J Dermatol; 2006 Jul; 155(1):156-9. PubMed ID: 16792768
[TBL] [Abstract][Full Text] [Related]
6. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis.
Krueger G; Callis K
Arch Dermatol; 2004 Feb; 140(2):218-25. PubMed ID: 14967799
[TBL] [Abstract][Full Text] [Related]
7. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
Gisondi P; Cotena C; Tessari G; Girolomoni G
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
[TBL] [Abstract][Full Text] [Related]
9. [Long-term safety and efficacy of etanercept in the treatment of psoriasis].
Zaragoza V; Pérez A; Sánchez JL; Oliver V; Martínez L; Alegre V
Actas Dermosifiliogr; 2010; 101(1):47-53. PubMed ID: 20109392
[TBL] [Abstract][Full Text] [Related]
10. Etanercept in psoriasis treatment.
Pietrzak A; Chodorowska G; Urban J; Roliński J; Pietrzak B
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):222-6. PubMed ID: 15314989
[TBL] [Abstract][Full Text] [Related]
11. Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy.
Pomerantz RG; Mody E; Husni ME; Qureshi AA
J Drugs Dermatol; 2009 Apr; 8(4):406-12. PubMed ID: 19363860
[TBL] [Abstract][Full Text] [Related]
12. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
Sfikakis PP
Curr Dir Autoimmun; 2010; 11():180-210. PubMed ID: 20173395
[TBL] [Abstract][Full Text] [Related]
13. Two years of experience with etanercept in recalcitrant psoriasis.
Ahmad K; Rogers S
Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
[TBL] [Abstract][Full Text] [Related]
14. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice.
Barrera MV; Habicheyn S; Mendiola MV; Herrera Ceballos E
Eur J Dermatol; 2008; 18(6):683-7. PubMed ID: 19049936
[TBL] [Abstract][Full Text] [Related]
15. Etanercept for the treatment of psoriasis.
Bissonnette R
Skin Therapy Lett; 2006 Feb; 11(1):1-4. PubMed ID: 16485060
[TBL] [Abstract][Full Text] [Related]
16. Etanercept for the treatment of psoriasis and psoriatic arthritis.
Gottlieb AB
Dermatol Ther; 2004; 17(5):401-8. PubMed ID: 15379775
[TBL] [Abstract][Full Text] [Related]
17. Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study.
Koc E; Tunca M; Akgul EO; Akar A; Kurt Y; Kurumlu Z; Erbil K; Kilic S
J Dermatol; 2009 Apr; 36(4):191-6. PubMed ID: 19348656
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of etanercept for the treatment of psoriasis: an overview of the Italian clinical experience from the real-life setting and independent studies.
Vena GA; Cassano N; Piaserico S; Conti A; Girolomoni G
Immunopharmacol Immunotoxicol; 2012 Dec; 34(6):901-6. PubMed ID: 22686544
[TBL] [Abstract][Full Text] [Related]
19. Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence.
Foley PA; Quirk C; Sullivan JR; Dolianitis C; Hack SP; Thirunavukkarasu K; Cooper AJ
J Eur Acad Dermatol Venereol; 2010 Oct; 24(10):1135-43. PubMed ID: 20337816
[TBL] [Abstract][Full Text] [Related]
20. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
